Back

Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results

1 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Secondary prevention: a multifactorial approach Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

9 More presentations in this session

Presentation thumbnail
Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario
Miss C. Frketich (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Variability of pre-test probability for obstructive coronary artery disease between referring primary care physicians and estimations from the referral letters
Mr E. Stertman (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Integrated care using the ABC-stroke pathway improves cardiovascular outcomes and survival in patients with recent ischaemic stroke: a population-based cohort study
Doctor S. Choi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study
Ms M. Sakalaki (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
National dispensing of evidence-based treatment for New Zealand patients before and after peripheral arterial or percutaneous coronary procedures; undertreatment in plain sight.
Associate Professor S. Wells (Auckland, NZ)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention: a multifactorial approach

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Session
Late-breaking science on pharmacology
thumbnail
Congress Presentation
What have we learned? Long-term safety and efficacy of inclisiran
thumbnail
Congress Presentation
Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources